Sentien Biotechnologies, Inc., a Cambridge, MA-based clinical-stage biotechnology company developing novel approaches to cell therapy, closed a $12m Series A funding.
The round was co-led by Boehringer Ingelheim Venture Fund USA, Inc. (BIVF USA) and BioInnovation Capital, with participation from Chiesi Ventures, MBL Venture Capital Co., Ltd, and Mass Medical Angels. In conjunction with the financing, Johannes Fruehauf, M.D., Ph.D., general partner of BioInnovation Capital, and Giacomo Chiesi, M.B.A., will join Sentien’s board of directors. Richard Ganz, M.B.A., and Martin Heidecker, Ph.D., managing director of BIVF, USA, will continue to serve on the Sentien board, with Mr. Ganz serving as chairman.
The company will used the funds for the initial clinical development of its SBI-101 for the treatment of acute kidney injury (AKI).
Led by Brian Miller, CEO, Sentien is a clinical stage company developing novel approaches to cell therapy. Its lead product, SBI-101, combines mesenchymal stromal cells (MSCs) within an approved blood-filtration device, allowing for controlled, sustained delivery of MSC secreted factors. This product is being tested to treat systemic inflammatory diseases where MSCs can condition blood continuously during an acute illness.